Drug
TD 1058
TD 1058: highest development phase Phase 1, developed by Theravance Biopharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| TD-1058 NCT04589260 | Phase 1 | Idiopathic Pulmonary Fibrosis (IPF) |
Latest
No recent events.
Follow TD 1058 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.